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ABSTRACT
Literature Review on Prediction Models for
Atherosclerotic Cardiovascular Diseases
Hyun-Hee Park
Graduate School of
Public Health
Yonsei University
(Directed by Professor Sun Ha Jee, Ph.D.)
Introduction: Atherosclerotic Cardiovascular Diseases (ASCVD) is a major
cause of death worldwide. The Framingham study has overestimated
ASCVD risk in some populations, which has led to the concern that scores
may be inappropriate for other populations. Thus, the development of
prediction models for ASCVD has been meticulously studied.
Objectives: Past to modern predictive models were analyzed based on
their general characteristics, models and outcomes of general
characteristics, risk factors, and predictors through a systematic review of
literature.
Methods: The literature searches were carried out with the literature
databases PubMed and Google Scholar. This study reviewed the general
characteristics, models and outcomes of the general characteristics, and
general risk factors of the prediction models, and grouped the
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Keywords: Atherosclerotic Cardiovascular Diseases, study, general
characteristics, risk factors, predictors
characteristics of the variable factors into the following three categories:
those in the USA, those in other countries, and those in validation and
calibration studies.
Results: The statistical analysis showed a trend from the logistic
regression model to the Cox proportional hazards model in the USA, in
other countries, and in the validation and calibration study.
The definition of the outcomes was expanded from CHD and not CHD to
Hard CHD or CVD in the USA. In the studies on other countries, the
outcomes were defined as ICD codes and the incidence of CVD or the
death probabilities, and whether they were Hard CHD or CVD. In the
validation and calibration study, the definition of the outcomes was
expanded to ASCVD.
For the general risk factors of the prediction model, the simple
cholesterol, was combined with the expanding variables such as DM,
smoking, the family history, the HTN medication, statin therapy, and
exercise.
Conclusion: The results of this study provide important baseline
information for prediction models for ASCVD.
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І. INTRODUCTION
1. Background
Atherosclerotic cardiovascular diseases (ASCVD) is one of the leading
causes of premature death and a major cause of disability in South Korea
(National Statistical Office, 2013). According to the World Health
Organization (WHO), 1.2 million people reportedly die from coronary heart
disease (CHD) and stroke each year (WHO, 2005). Focusing on a single
risk factor such as high blood pressure or serum cholesterol was not
enough; an approach was needed that accounted for the multifactorial
origin of cardiovascular disease (CVD). The requirements for
comprehensive management of patients at high risk of CVD has increased
(Jackson, 2000).
In previous researches, prediction models were derived from multivariable
mathematical functions that assigned weights to major CHD risk factors
such as sex, age, blood pressure, total cholesterol (TC), low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), smoking behavior, and diabetes status (Jackson et al., 2005).
This knowledge led to the development of multivariable risk prediction
algorithms that incorporate risk factors (D’Agostino et al., 2008) that can
be used by primary care physicians to assess individual patients’ risk of
developing all types of atherosclerotic CVD (Conroy et al., 2003) or specific
components of CVD, CHD (Anderson et al., 1991), stroke (Wolf et al.,
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1991), peripheralvascular disease (PVD) (Murabito et al., 1997), or heart
failure (HF) (Kannel et al., 1999).
Multivariable assessment has supported the estimation of the absolute
CVD risk and guided the treatment of risk factors (British Cardiac Society,
2005; Jackson et al., 2005; Ahn et al., 2006; and D’Agostino et al., 2008).
The Framingham heart study has developed mathematical functions for
predicting the risk of clinical CHD events. The primary purposes were to
treat patients and decrease their risk assessment indicators in clinical trials,
and prevent and control the disease (Kannel et al., 1976).
However, there are limitations in the application of the risk functions
obtained from the Framingham study (Jee et al., 2008). Many guidelines
recommend estimating the risk of CVD by combining different risk factors
into a numeric estimate of risk (Cox et al., 2007). Recalibration of the
Framingham functions could permit various regions of the world to adapt
the Framingham tools to local populations (Liu et al., 2004). Directly
applying the Framingham functions in some populations were overestimate
the CHD risk (Hense et al., 2003).
Therefore, many countries developed a more accurate individual prediction
model with modifications of the existing model (Hense et al., 2003; Liu J
et al., 2003; Marrugat et al., 2003; Neuhauser et al., 2003; and Simons et
al., 2003).
According to the guidelines that the American Heart Association (AHA)
and the American College of Cardiology (ACC) released on November 13,
2013 for the management of cholesterol as a major step in the right
direction (Paul et al., 2013), the ACC-based algorithm recommends the
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initiation of statin therapy in primary prevention patients with a predicted
10-year risk of greater than or equal to 7.5% (Kavousi et al., 2014; Munter
et al., 2014). These new criteria could result in the recommendation that
statin therapy be considered in the more than 45 million middle-aged
Americans who do not have CVD (33,090,000 at ≥7.5% 10-year risk and
12,766,000 at >5.0-7.4% 10-year risk). This number is equivalent to about
one in every three American adults, many of whom are already on statin
treatment under the older US guidelines (Stone et al., 2013).
This study reviewed the general characteristics, models, and outcomes of
the general characteristics and general risk factors of prediction models,
and the characteristics of the variable factors into the following three
categories: in the USA, in other countries, and in validation and calibration
studies.
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2. Objectives
Past to modern predictive models were analyzed based on their general
characteristics, risk factors, and predictors in the systematic review of
literature. The analysis would contribute to the baseline for the prevention
and management of ASCVD.
The specific objectives of the analysis are as follows.
1. To trace the history of ASCVD in prediction models.
2. To analyze the general characteristics of the Framingham study among
individual studies in the USA, other countries, and validation and
calibration studies.
3. To provide important information on the baseline in the prediction
models for ASCVDs.
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II. MATERIALS AND METHODS
Past to modern predictive models were analyzed Twenty-one of them met
the inclusion criteria. They were classified into three categories: those who
had participated in the Framingham Study in the USA (seven), those who
had participated in the prediction of several countries’ models (seven), and
those who had articles of validation and calibration multiple cohorts
(seven). Each individual empirical investigation was carefully evaluated
according to the following central methodological points: (1) general study
characteristics, (2) models and outcomes of the general characteristics, (3)
General risk factors of the prediction models, and (4) the characteristics of
the predictors. The literature searches were carried out with the literature
databases PubMed, Google Scholar, Circulation, JAHA (Journal of the
American Heart Association), JAMA (Journal of the American Medical
Association), ELSEVIER, JCD (Journal of Chronic Diseases), European
Society of Cardiology, MJA (Medical Journal of Australia), NMCD
(Nutrition, Metabolism, and Cardiovascular Diseases), BMJ (British Medical
Journal), Cardiologia, researchgate, ACP (Annals of Internal Medicine),
KOSIS (Korean Statistical Information Service), and Lancet, as well as
with online databases.
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III. RESULTS
1. General study characteristics
1.1. General study characteristics in the USA
Table 1. Cornfield (1962), Jeanne et al. (1967), Kannel et al. (1976), and
Pencina et al. (2009) all used the Framingham Study. Anderson et al.
(1991), Wilson et al. (1998), and D’Agostino et al. (2008) used the
Framingham Study and the Framingham Offspring Study.
Kannel et al. (1976) performed the Framingham Study on a total of 5,209
subjects with a follow-up period of 12 years. However, we searched for
the more classic study of Cornfield (1962). The results showed that serum
cholesterol and systolic blood pressure are risk factors of CHD in the
Framingham, Massachusetts cohort. A multivariate analysis of the risk of
CHD over 12 years was performed (Jeanne et al., 1967). The standard risk
factors remained strong predictors of hard CVD over the extended
follow-up period. Thirty-year risk prediction functions offer additional risk
burden information that complements that of the 10-year functions
(Pencina et al., 2009).
Many researchers have used, developed, and provided to people the
Framingham Study.
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Author* Year Population F/U†(year) Cohort nameTotal Men Women
Cornfield 1962 1,329 1,329 - 6 FHS
Jeanne 1967 4,856 2,187 2,669 12 FHS
Kannel 1976 5,209 - - 8 FHS
Anderson 1991 5,573 - - 1968-
75/12§
FHS, FOS
Wilson 1998 5,345 2,489 2,856 12 FHS, FOS
D'Agostino 2008 8,491 3,969 4,522 12 FHS, FOS
Pencina 2009 4,506 2,173 2,333 30 FHS
Table 1. General study characteristics (intended subject, f/u year,
and cohort name) in the USA
FHS = the Framingham Study; FOS = the Framingham Offspring Study
*The first author
†Follow- up years or period
§ From 1968 through 1975, and 12 years of follow-up were included.
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1.2. General study characteristics in other countries
Many guidelines recommend estimation of the risk of CVD by combining
different risk factors into a numeric estimate of risk (Cox et al., 2007).
Therefore, many countries published new prediction models for their own
people.
Table 2. The study estimated the 10-year risk of fatal CVD in Europe
(Conroy et al., 2003). The Dubbo Study derived a simple CVD risk
function specifically for elderly Australians, which uses risk factors readily
accessible to all medical practitioners (Simons et al., 2003). The original
Framingham functions overestimated the risk of CHD in the Chinese
multi-provincial cohort study (CMCS) participants (Liu et al., 2004). New
tools for predicting the CVD risk were derived from the Italian population
studies of Riskard (2005) and Menotti et al. (2005). The NIPPON DATA80
Research Group (2006) conducted a risk assessment of death from CVD
based on a 19-year follow-up study of a Japanese representative
population, which was used as a health education tool for lifestyle
modification-targeting individuals with CVD risk factors. The study derived
and validated the QRISK and the new CVD risk score ASSIGN for the
United Kingdom (UK) (Cox et al., 2007). The study developed a stroke
risk prediction model for Koreans with a high risk of stroke (Jee et al.,
2008).
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Author* Year Country
Population F/U
year
†
Cohort nameTotal Men Women
Conroy 2003 Europe 205,178 117,098 88,080 10 Finland The FINRISK Study
Russia Collaborative
US-USSR study on
the prevalence of
dyslipoproteinemias
and ischemic heart
disease in American
and Soviet populations
Norway Norwegian Counties
Study
UK BRHS
UK
Scotland
Scottish Heart Health
and Scottish MONICA
cohort follow-up
studies
Denmark The Glostrup
Population Studies
Sweden The Primary
Prevention Study in
Göteborg (Gothenburg)
Belgium BIRNH
Germany The MONICA
Augsburg
Italy RIFLE
France Paris Prospective
Study
Spain Catalonia Cohort
Study, Barcelona
Multifactorial Trial,
Factory Heart Study
Simons 2003 Australia 2,805 1,233 1,572 5/10 The Dubbo Study
Liu 2004 China 3,0121 16,065 14,065 10 CMCS
Menotti 2005 Italy 17,153 12,045 5,108 5/10
/15
Gruppo di Ricerca per la Stima
del Rischio Cardiovascolare
NIPPON
DATA80
2006 Japan 9,353 4,098 5,255 10 The NIPPON DATA80 study
Cox 2007 UK Derivation cohort 1995
/200
7
/10
‡
Derivation and validation cohort
of QRISK, ASSIGN score1.28§ 636,753 646,421
Validation cohort
0.61§ 305,140 309,413
Jee 2008 Korea 1,22§ 777,502 446,238 13 KCPS
Table 2. General study characteristics (intended subject, f/u year, and
cohort name) in other countries
US-USSR = the United States and in the Union of Soviet Socialist Republics; BRHS = British Regional
Heart Study; BIRNH = Belgian Interuniversity Research on Nutrition and Health; MONICA = Monitoring Of
Trends and determinants In Cardiovascular disease surveys; RIFLE = Risk Factors and Life Expectancy;
CMCS = the Chinese Multi-provincial Cohort Study; NIPPON DATA= National Integrated Project for
Prospective Observation of Non-communicable Disease And its Trends in the Aged prediction algorithm for
CVD that uses traditional risk factors; KCPS = the Korean Cancer Prevention Study * The first author †
Follow- up years or period ‡From1 January 1995 and 1 April 2007, 10 -year risk predictions § million
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1.3. General study characteristics in the validation and calibration
study
Table 3. The Framingham Study in the USA validated and calibrated the
CHD and CVD prediction scores. All the analyses were sex- and
race-specific, and the prediction functions performed well among whites
and blacks in different settings and can be applied to other ethnic groups
such as ARIC, PHS, HHP, PR, SHS, and CHS (D’Agostino et al., 2001).
The MONICA Augsburg and PROCAM cohorts in Germany compared the
observation and prediction of coronary risk (Hense et al., 2003). The Spain
cohort of the Girona REGICOR calibrated the Framingham Study
(Marrugat et al., 2003). The study was based on an analysis of data from
the Health Survey for England (HSE) in 1998 and 1999 for the
development of a simple method of adjusting the Framingham equation to
estimate coronary risk in South Asians, which could then be applied to
existing simple paper-based tools (Aarabi et al., 2005). These equations
were calibrated and differentiated to predict the ASCVD risk in a
contemporary population-based cohort, that of the REasons for Geographic
And Racial Differences in Stroke (REGARDS) Study (Muntner et al., 2014).
The CHD risk model was compared with the Framingham CHD risk score
in the Korean Heart Study (KHS) population (Jee et al., 2014). The
calibration and discrimination were analyzed among multiple cardiovascular
risk scores in a modern multi-ethnic cohort (DeFilippis et al., 2015).
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Author* Year Country
Population F/U
year
†
Sample
model
Analysis
CohortTotal Men Women
D'Agostino 2001 USA 38,137 23,424 14,713 5 FHS ARIC, PHS,
HHP, PR,
SHS, CHS
Hense 2003 Germany MONICA Augsburg 13.27.8
FHS MONICA
Augsburg ,
PROCAM5,786 2,861 2,925
PROCAM 11.6‡11.1§8,682 5,527 3,155
Marrugat 2003 Spain 200,000 - - 10 FHS Ginona
Aarabi 2005 UK
South
Asians
1548 - - 10 FHS HSE
Jee 2014 Korea 268,315 164,005 104,310 11.6 FHS KHS
Muntner 2014 USA 30,239 - - 10 ACC/AHA
pooled
Cohort
risk
Equations
REGARDS
DeFilippis 2015 USA 4227 1961 2266 10.2 AHA/
ACC/
ASCVD
score
MESA
Table 3. General study characteristics (intended subject, f/u year, and
cohort name) in the validation and calibration study
FHS = the framingham study; ARIC = the Atherosclerosis Risk in Communities Study(1987-1988); PHS
= Physicians’ Health Study(1982); HHP = Honolulu Heart Program(1980-1982); PR =Puerto Rico Heart
Health Program (1965-1968); SHS = Strong Heart Study(1989-1991); CHS = Cardiovascular Health
Study(1989-1990); MONICA = Monitoring Of Trends and determinants In Cardiovascular disease
surveys; PROCAM = Prospective Cardiovascular Muenster Study from northwestern Germany; Girona
= the Spanish population study; HSE = the Health Survey for England; ACC/AHA =American
College of Cardiology and the American Heart Association; REGARDS = the REasons for Geographic
And Racial Differences in Stroke study; KHS = the Korean Heart Study; MESA = Multi-Ethnic
Study of Atherosclerosis
* The first author
†Follow- up years or period
‡male § female
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2. Models and outcomes of the general study
characteristics
2.1. Characteristics of the statistical analysis models and
discriminative outcomes in the USA
2.1.1 Characteristics of the statistical analysis models
Table 4. The logistic regression model for conditional risk was assumed
that was, the probability that the disease was manifested in a specified
time period given a set of variables from the data. The estimation was
based on the method of Walker-Duncan (Kannel et al., 1976). The
parametric model used was seen to have several advantages over existing
standard regression models. Unlike logistic regression, it can provide
predictions for different lengths of time, and express probabilities in a more
straightforward way than in the Cox proportional hazards model (Anderson
et al., 1991). The Cox proportional hazards regression assumed that on
each individual are available values of one or more explanatory variables.
The hazard function (the age-specific failure rate) is taken to be a
function of the explanatory variables and unknown regression coefficients
multiplied by an arbitrary and unknown function of time (Cox, 1972). The
statistical tests included age-adjusted linear regression or logistic
regression to test for trends across the blood pressure, TC, LDL-C, and
HDL-C categories (Wilson et al., 1998).
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2.1.2 Characteristics of the discriminative outcomes
Table 4. The case with one variable and in which those who had CVD
and those who did not (NCHD) were considered two separate populations
experienced a new coronary event during the study period (Cornfield,
1962). CHD included all forms of definite myocardial infarction, coronary
insufficiency, angina pectoris, and death from CHD (Jeanne et al., 1967).
As in all previous publications that reported results in Framingham, the
subjects lost to the follow-up were treated as not CHD patients, so they
were investigated. The definition of the outcome included CVD and CHD
(Kannel et al., 1976), and myocardial infarction in CVD (Anderson et al.,
1990). The study was followed up over a 12-year period for the
development of CHD (angina pectoris, recognized and unrecognized
myocardial infarctions, coronary insufficiency, and CHD death), according to
previously published criteria (Wilson et al., 1998). CVD was designated as
a composite of CHD cerebrovascular events, peripheral artery disease, and
HF (D’Agostino et al., 2008 and Pencina et al., 2009). In the past, CHD
and CVD outcomes were differentiated in a narrow sense; but in recent
years, outcomes started being defined as comprehensive hard CHD.
- 14 -
Author* Model Outcome Definition of outcome
Cornfield Logistic CHD CHD(MI or AP), NCHD
Jeanne Logistic CHD CHD(MI, coronary insufficiency, AP and death
from CHD)
Kannel Logistic CVD CVD, CHD, ABI, hypertensive heart disease and
intermittent claudication
Anderson parametric CVD MI(including silent and unrecognized MI); death
from CHD(sudden or non-sudden); CHD
(consisting of MI and CHD death plus AP and
coronary insufficiency); stroke, including TIA;
CVD(including all the above plus CHF and PVD);
and death from CVD(CVD death)
Wilson Cox CHD Hard CHD: AP, recognized and unrecognized MI,
coronary insufficiency, and CHD death
D'Agostino Cox CVD CVD as a composite of CHD (coronary death, MI,
coronary insufficiency, and angina), CVD events
(including ischemic stroke, hemorrhagic stroke,
and TIA), PAD(intermittent claudication), and HF
Pencina Cox CVD Hard CVD: composite oh hand CHD(coronary
death, MI) and stroke(fatal and nonfatal)
Table 4. Characteristics of the statistical analysis models and
discriminative outcomes in the USA
Logistic = logistic regression model; Cox = the Cox proportional hazards model; CVD =
cardiovascular disease; CHD= coronary heart disease; NCHD = not coronary heart disease; MI =
myocardial infarction; AP = angina pectoris; ABI = atherothrombotic brain infarction; TIA =
transient ischemic attack; PAD = peripheral artery disease; CHF = congestive heart failure; PVD
=peripheral vascular disease; HF = heart failure * The first author
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2.2. Characteristics of the statistical analysis models and
discriminative outcomes in other countries
2.2.1. Characteristics of the statistical analysis models
Table 5. The Weibull model was stratified by cohort and sex-that is,
separate hazard functions were calculated for men and women in each of
the component cohorts, but the risk factor coefficients were calculated from
the whole dataset (Conroy et al., 2003).
The absolute 10-year risk of hard CHD was predicted with the Cox
regression model developed by Framingham investigators, wherein P = 1 -
S(t)exp(f[x,M]) and f(x,M) = β1(x1-M1) + . . . + βp (xp - Mp). Here, β1 . . . ,p
are the regression coefficients, x1 . . . xp represent individualficients, the
xHD 1 . . . Mp are the mean values of the risk factors in the cohort, and
S(t) is the survival rate at the mean values of the risk factors at time t (t
= 10 years) (D’Agostino et al., 2001 and Liu et al., 2003).
The Weibull statistical analysis model is used in Europe (Conroy et al.,
2003); the logistic regression model, in Australia (Simons et al., 2003); and
the Cox regression model, in China (Liu et al., 2003), Italy (Menotti et al.,
2005), Japan (NIPPON DATA80, 2006), the UK (Cox et al., 2007), and
Korea (Jee et al., 2008).
2.2.2. Characteristics of the discriminative outcomes
Table 5. The outcome was defined based on the International Classification
of Disease (ICD) codes in Europe (Conroy et al., 2003), CVD and hard
CHD in Australia (Simons et al., 2003), coronary death and myocardial
infarction of hard CHD in China (Liu et al., 2003), major CVD in Italy
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Author* Country Model Outcome Definition of outcome
Conroy Europe Weibull CVD ICD-9 codes 401- 414, 426 -443, exception
non- atherosclerotic causes of death: 426.7,
429.0, 430.0, 432.1, 437.3, 437.4, and 437.5,
798.1(instantaneous death) and 798.2(death
within 24h of symptom onset) as
cardiovascular deaths
Simons Australia Logistic CVD incidence of CVD, MI, coronary death ot
stroke
Liu China Cox CHD Hard CHD: coronary death and MI
Menotti Italy Cox CVD major coronary, cerebrovascular and
cardiovascular events
NIPPON
DATA80
Japan Cox CVD death probabilities: CHD, stroke, and all
CVD
Cox UK Cox CVD MI, CHD, stroke, and TIA
Jee Korea Cox CVD stroke: ischemic stroke, hemorrhagic stroke
(Menotti et al., 2005), combined CVD and CHD via CVD in Japan
(NIPPON DATA80, 2006), and major CVD in the UK (Cox et al., 2007).
The incidence of stroke included whole and subtype incidences of ischemic
and hemorrhagic stroke (Jee et al., 2008).
Table 5. Characteristics of the statistical analysis models and
discriminative outcomes in other countries
Weibull = Weibull proportional hazards model; Logistic = logistic regression model; Cox = the
Cox proportional hazards model; ICD = Internation Classification of Disease; CVD =
cardiovascular disease; CHD= coronary heart disease; MI = myocardial infarction; TIA = transient
ischemic attack
* The first author
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2.3. Characteristics of the statistical analysis models and
discrimination of the outcomes in the validation and calibration study
2.3.1. Characteristics of the statistical analysis models
Table 6. The Cox proportional hazards model yielded regression
coefficients for the Framingham and non-Framingham cohorts (D’Agostino
et al., 2001). The Framingham equations were able to correctly predict
CHD events using receiver operating characteristic (ROC) (Hense et al.,
2003) analyses and computations of areas-under-the-curve (AUC-statistic)
(Hanley and McNeil, 1983), as well as the procedures suggested by Miller
et al. (1991). The Cox model used a reliable estimation of the local risk
factor prevalence, as well as the local coronary event incidence rate
considered, and the original equation coefficients (Marrugat et al., 2003).
The ROC plot was used to compare the different adjustments in the
primary role of identifying individuals above or below a given risk
threshold (Aarabi et al. 2005).
Cox proportional hazards regression models were fitted to the Korean
CHD risk score (KRS) with the basic model using the continuous form of
the Net Reclassification Index (NRI) for the 10-year risk of CHD (Jee et
al., 2014). The calibration of the Pooled Cohort risk equations was
determined using the observed and predicted numbers of ASCVD events
(Muntner et al., 2014) at a five-year follow-up in each decile and a
modified Hosmer-Lemeshow chi-square statistic (Harrell et al., 1996). The
Cox-statistic used as models the Framingham risk score (FRS), the
original Framingham risk prediction algorithm to predict CHD (FRS-CHD),
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and the Adult Treatment Panel III (ATPIII), and recommended a modified
FRS (ATPIII-FRS-CHD) (DeFilippis et al., 2015).
2.3.2. Characteristics of the discriminative outcomes
Table 6. Definition of the outcome: a hard CHD (D’Agostino et al., 2001);
ICD-9 (Hense et al., 2003); hard coronary events (Marrugat et al., 2003);
CHD, CVD, angina, MI, stroke, or treatment with lipid-lowering drugs in
CD (Aarabi et al., 2005); non-fatal CHD events (acute myocardial infarction
or code I21) in hard CHD (Jee et al., 2014); a hard ASCVD event as an
ICD-9 code in ASCVD (Muntner et al., 2014); and MI or death due to
CHD or CVD in ASCVD (DeFilippis et al., 2015).
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Author* Country Model Outcome Definition of outcome
D'Agostino USA Cox CHD Hard CHD: events, defined as
coronary death or MI
Hense Germany ROC
analyses,
AUC
statistic
CHD The ninth revision of (ICD-9)
non-fatal MI and fatal coronary
events
Marrugat Spain Cox CHD Hard coronary events (sympto
-matic AMI, fatal or non fatal), MI
Aarabi UK
South
Asians
ROC
analyses
CD CHD, CVD, angina, MI, stroke or
treatment with lipid-lowering drugs
Jee Korea Cox CHD Hard CHD events, comprising acute
MI, sudden death and other
coronary deaths, non-fatal CHD
events(AMI, code I21)
Muntner USA χ2 ASCVD Hard ASCVD events: non-fatal MI,
CHD death and non-fatal or fatal
stroke, AF or HF. ICD-9 code of
410.×× (except 410.×2 which
indicates a subsequent episode of
care) in any position and stroke
events were defined by a discharge
diagnosis ICD9 code of 430.××,
431.××, 433.××, 434.×× or 436.×
DeFilippis USA Cox ASCVD MI; definite or probable angina;
resuscitated cardiac arrest; stroke
(not TIA); or death due to CHD,
stroke, atherosclerosis, or other
CVD
Table 6. Characteristics of statistical analysis models and
discriminative outcome in validation and calibration
Cox = the Cox proportional hazards model; ROC = receiver operating characteristic; AUC =
areas-under-the curve; x2 = Hosmer-Lemeshow Chi-squared; CHD= coronary heart disease; ICD
= Internation Classification of Disease; MI = myocardial infarction; CVD = cardiovascular disease;
CD = coronary disease; AMI = Acute Myocardial Infarction; AF = atrial fibrillation; HF = Heart
Failure; ASCVD =arteriosclerotic cardiovascular disease; TIA = transient ischemic attack;
* The first author
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3. General risk factors of the prediction models
3.1. General risk factors of the prediction models in the USA
Table 7. The study exposed combinations of serum cholesterol and SBP in
CHD (Cornfield, 1962). Seven risk factors measured in the initial
examination were investigated (Jeanne et al., 1967), and seven risk factors
without BMI were used (Kannel et al., 1976). The potential importance of
controlling multiple risk factors demonstrated that total cholesterol and
HDL cholesterol are of little statistical significance because it might be
expected that an equation developed to predict CHD would not be
particularly effective in estimating the risk of stroke (Anderson et al.,
1990). Sex-specific prediction equations were formulated to predict the
CHD risk according to the age, diabetes, smoking habit, JNC-V blood
pressure categories, and NCEP total cholesterol and LDL cholesterol
categories (Wilson et al., 1998). Sex-specific multivariable risk functions
(sex-specific multivariable risk functions, total cholesterol, and LDL
cholesterol categories) might be expected from an equation developed for
treatment of hypertension, smoking, and diabetes (D’Agostino et al., 2008).
The standard risk factors measured at the baseline were significantly
related to the incidence of hard CVD, upon which BMI loses its
significance. This finding illustrates how the effect of BMI is mediated
through other risk factors (Pencina et al., 2009).
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Author* Age
Cholesterol BP
Smoking ECG
SG/
DM/
Hb
BMI HTN-medTC HDL LDL TG SBP DBP
Cornfield ● ● - - - ● - - - - - -
Jeanne ● ● - - - ● - ● ● ● ● -
Kannel ● ● - - - ● - ● ● ● - -
Anderson ● ● ● - - ● ● ● ● ● - -
Wilson ● ● ● ● - ● ● ● - ● ● -
D'Agostino ● ● ● - - ● - ● - ● - ●
Pencina ● ● ● ● ● ● - ● - ● - ●
Table 7. General risk factors of the prediction models in the USA
BP = blood pressure; ECG = electrocardiography; SG = serum glucose; DM = Diabetes Mellitus;
Hb = hemoglobin; BMI = body mass index; HTN = Hypertension; HTN med. = Hypertension
medication; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low density
lipoprotein; TG = triglyceride; SBP = systolic blood pressure; DBP =diastolic blood pressure
* The first author
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3.2. General risk factors of the prediction models in other countries
Table 8. The guidelines for risk factor management issued by the first
joint task force of the European societies on coronary prevention (Pyy Gui
et al., 1994) used a simple risk chart in Europe (Conroy et al., 2003). CVD
incidence significantly predicted factors in Australia (Simons et al., 2003).
CVD incidence was assigned as the end-point in the comparisons of the
risk factors in China (Liu et al., 2003). The risk factors used in the
estimate were the sex, age, SBP, serum cholesterol, diabetes, and cigarette
smoking in Italy (Menotti et al., 2005) and Japan (NIPPON DATA80, 2006).
The risk factors in the UK were the age, sex, smoking status, SBP, ratio
of the total serum cholesterol to the HDL, BMI, family history of CHD in
a first-degree relative aged less than 60, area measure of deprivation, and
existing treatment with an antihypertensive agent in the UK (Cox et al.,
2007). The risk factors of stroke were the age, systolic blood pressure,
diabetes, total cholesterol, cigarette smoking, physical activity, BMI, and
alcohol intake (Jee et al., 2008).
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Author* Country
A
g
e
Cholesterol BP
SG/
DM
F
H
E
C
G
B
M
I
H
T
N
‡
Smo
king
Drin
king
Exer
ciseT
C
HD
L
SB
P
DB
P
Conroy Europe ● ● ● ● - - - - - - ● - -
Simons Australia ● ● ● ● - ● - - - ● ● - -
Liu China - ● ● ● ● ● - - - - ● - -
Menotti Italy ● ● - ● - ● - - - - ● - -
NIPPON
DATA80 Japan ● ● - ● - ● - - - - ● - -
Cox UK ● ● ● ● - ● ● ● ● ● ● - -
Jee Korea ● ● - ● - ● - - ● ●§ ● ● ●
Table 8. General risk factors of the prediction models in other
countries
BP = blood pressure; SG = serum glucose; DM = Diabetes Mellitus; FH = family history; ECG
= electrocardiography; HTN = Hypertension; HTN-med.= HTN medication status; BMI = body
mass index; TC = total cholesterol; HDL = high-density lipoprotein; LDL = low density
lipoprotein; SBP = systolic blood pressure; DBP =diastolic blood pressure;
* The first author ‡HTN medication § SBP≥140, DBP≥90
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3.3. General risk factors of the prediction models in the validation
and calibration study
Table 9. Sex- and race-specific JNC-V blood pressure and NCEPATP II
cholesterol categories, along with age, current smoking habit, and presence
of diabetes, related to the occurrence of hard CHD events (D'Agostino et
al., 2001). The prediction equations were based on individual risk factor
levels that included the age, SBP, TC/HDL ratio, and dichotomous diabetes
and smoking variables, and used censored times to the event (Hense et al.,
2003). The different adjustments investigated were fixed increments of the
age, TC, and TC:HDL ratio, and multipliers of the TC:HDL cholesterol
ratio (Aarabi et al., 2005). The risk factors were the age, blood pressure,
total and HDL-C, diabetes, and smoking. In addition, triglycerides and
LDL-C were considered for inclusion in the KRS (Jee et al., 2014).
Information on the participants’ age, race, sex, smoking status, prior
diagnosed co-morbid conditions, and use of antihypertensive and
anti-diabetes medications was collected (Muntner et al., 2014). These risk
scores were compared in the age-, sex-, and race-balanced medical
history, anthropometric measurements, and laboratory data such as HbA1c,
hs-CRP (DeFilippis et al., 2015).
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Author* Country
R
a
c
e
A
g
e
Cholestero
l BP SG/
DM
B
M
I
F
H
H
T
N§
Smo
king
Statin
thera
py
hs
-
C
R
P
T
C
H
D
L
L
D
L
S
B
P
D
B
P
D'Agostino USA ● ● ● ● - ● ● ● - - - ● - -
Hense Germany - ● ● ● - ● - ● - - - ● - -
Marrugat Spain - ● ● ● - ● ● ● - - - ● - -
Aarabi UK - ● ● ● - ● - - - - - - - -
Jee Korea - ● - ● ● ● ● ● - - - ● - -
Muntner USA ● ● ● ● ● ● - ● - - ● ● ● -
DeFilippis USA ● ● ● ● - ● - ●± ● ● ● ● - ●
Table 9. General risk factors of the prediction models in the
validation and calibration study
BP = blood pressure; SG = serum glucose; DM = Diabetes Mellitus; BMI = body mass index;
FH = family history; HTN = Hypertension; HTN-med.= HTN medication status; hs-CRP =
high-sensitivity C-reactive protein; TC = total cholesterol; HDL = high-density lipoprotein; LDL
= low-density lipoprotein; SBP = systolic blood pressure; DBP =diastolic blood pressure; HbA1c =
hemoglobin A1c
* The first author
± hemoglobin A1c(HbA1c)
§ HTN medication status
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4. Characteristics of the predictors
4.1. Characteristics of the predictors in the USA
Table 10. The age and SBP were stratified continuous variables (Cornfield
,1962; Jeanne et al., 1967; Kannel et al., 1976; Anderson et al., 1991; Wilson
et al., 1998; D'Agostino et al., 2008; and Pencina et al., 2009).
The questionnaire included questions about cigarette smoking, after which
the author made nominal variables. The ECG results were checked, and
then nominal variables were set up (Kannel et al., 1976; D'Agostino et al.,
2008; and Pencina et al., 2009).
The self-reported HTN medication was ascertained as a nominal variable
(D'Agostino et al., 2008 and Pencina et al., 2009).
Table 11. All the authors decided that cholesterol was a risk factor of
ASCVD, so the bell-Kendall technique or standardized enzymatic methods
were used. Also, glucose/DM/Hb were found to be important predictors of
CVD and CHD, as were the fasting plasma glucose and the combined DM
history or medication (Wilson et al., 1998; D'Agostino et al., 2008; and
Pencina et al., 2009).
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Author* Age SBP(mmHg)
DBP
(mmHg)
Smoking
(cigarette) ECG
HTN-
med.
Confield 40-59 log10
(BP-75)
<127
<127-146
147-166
167+
- - - -
Jeanne man:
30-39
40-49
50-62
women:
30-49
50-62
<129
130-139
140-149
≥150
- (1 day)
coded as
0 = never
1 = less than
a pack
2 = one pack
3 = more
than a pack
coded as
0 = normal
1 = left
ventricular
hypertrophy,
non-specific
abnormality,
intraventricular
block
-
Kannel 45-54
55-64
65-74
≥ 150 - current habits LVH -
Anderson 30-74 present coeffients for
the estimated
equations
1 = smoker
(quit within
last year)
0 = otherwise
1 = if definite
LVH
0 = otherwise
-
Wilson mean age
man:
48.±11.7
women:
49.8±12.0
JNC±-V definition use - -
D'Agostino mean age
49.30-74
left arm
(mean
SBP)
men:
129.7
women:1
29.7
- status:
self-report
- self
report
Pencina mean age
man:37.3
women:37
20-29
30-39
40-49
50-59
left arm - self-report - self
report
Table 10. Characteristics of the predictors in the USA
SBP = systolic blood pressure; DBP =diastolic blood pressure; ECG = electrocardiography;
ECG-LVH = electrocardiography left ventricular hypertrophy; HTN = hypertension; HTN-med.=
hypertension medication status * The first author ± Fifth Joint National Committee on
Hypertension = JNC-V definition: optimal SBP <120, DBP <80, normal SBP 120-129, DBP 80-84
high normal SBP 130-139, DBP 85-89, HTN stage I SBP140- 159, DBP 90-99 , HTN stage II–
IV SBP≥160, DBP≥100
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Author* Cholesterol HDL(mg/dl)
LDL
(mg/dl)
TG
(mg/dl) Glucose/DM/Hb
BMI
(kg/m2)
Cornfield mg/100cc
<200
200-219
220-259
260
- - - - -
Jeanne mg/100ml
<190
190-219
220-249
≥250
- - - Hemoglobin (g/100
ml)
<120
120-129
130-139
140-149
≥150
Relative
weight
<89
90-99
100-109
≥110
Kannel mg/l00ml
≥260
- - - glucose intolerance -
Anderson mg/dl
bell-Kendall
method
heparin
precipitat
ion
- - 1 = DM
0 = otherwise
(treatment with
insulin, oral
agents, fasting
glucose
≥ 140 mg/dl)
-
Wilson mg/dl
bell-Kendall
technique
TC <200,
200-239
240-279
≥280
<35
35-59
≥60
<130
130-159
≥160
- treatment insulin,
oral hypoglycemic
agents,
>150 mg/dL
(FPG)>140mg/dL
Height
weight
D'Agostino standardized enzymatic
methods
- - (mg/dL)
FPG ≥126 or>140
, insulin, oral
hypoglycemic
medications
-
Pencina standardized enzymatic
methods
Friede
-wald
formula§
standardiz
-ed
enzymatic
methods
(mg/dL)
FPG≥126 or >140
,insulin,
oral hypoglycemic
medications
Height
weight
Table 11. Characteristics of the predictors in the USA
HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglyceride; DM =
Diabetes Mellitus; Hb = hemoglobin; BMI = body mass index; FPG = fasting plasma glucose
* The first author
§ estimation of the concentration of low-density lipoprotein cholesterol in Plasma, without use of
the preparative ultracentrifuge
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4.2. Characteristics of the predictors in other countries
Table 12. In Europe, Australia, China, Italy, Japan, the UK, and Korea, the
continuous variables of the age and SBP were used. All these countries
used nominal variables in smoking. In most of the countries, two
categories for smoking were set up; but in Italy, four categories were used
(Menotti et al., 2005). The UK investigated the kind of blood pressure
medication used in the country (Cox et al., 2007). Korea asked about the
drinking frequency per day and used nominal variables (Jee et al., 2008).
Table 13. The designated important predictors were cholesterol and
glucose/DM. All the countries used cholesterol as a continuous variable,
and Italy used DM as a nominal variable. Most of the countries used the
fasting blood sample cholesterol, HDL triglycerides, and glucose/DM as
FPG but for the NIPPON data, the non-fasting blood glucose case was
used via the cupric-neocuproine method.
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Author* Country Age SBP(mmHg)
DBP
(mmHg) Smoking
Drin
king
HTN-
med. ECG
Conroy Europe 45-64 120 140
160 180
- nonsmoker
smoker
- - -
Simons Australia 60-79 measure - self-report
(yes/no)
- self
-report
-
Liu China 35-64 measure
rt arm
mean
value
Korotkoff
phase 5.
mean
value
current
smokers
- - -
Menotti Italy classes
years
45-49
50-54
55-59
60-64
65-69
70-74
4 classes
<130,
130-149
150-169
170+
- 4 classes
cigarettes
0
1-9
10-19
20+
(a day)
- - -
NIPPON
DATA
80
Japan mean
age
man:
50.3
women
:50.8
measure
Rt arm
5
categories
:
100-119
120–39
140–59
160–79
180–99
- 2
categories:
non-curre
nt smoker,
current
smoker
- - -
Cox UK 35-74 measure - current
smoker,
non-smok
er—includi
ng former
smoker
- (yes/no)§
—
antihypert
ensives,
thiazide,
β blocker,
CCB,
ACE
inhibitor
LVH
(yes
no)
Jee Korea mean
age
man
45
women
49.4
measure - never
ex-smoker
s
current
-smoker
g/
day
SBP≥140
DBP≥90
-
Table 12. Characteristics of the predictors in other countries
SBP = systolic blood pressure; DBP =diastolic blood pressure; ECG = electrocardiography; LVH =
left ventricular hypertrophy; HTN = Hypertension; HTN-med = HTN medication status; CCB =
calcium channel blocker; ACE inhibitor = angiotensin converting enzyme inhibitor
* The first author
§ current prescription of at least one antihypertensive
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Author* Country Cholesterol HDL Glucose/DM FM
BMI
(kg/m2) Exercise
Conroy Europe cholesterol/HDL ratio - - - -
Simons Australia 12-hour fast by
automated enzymatic
methods(mmol/L)
FPG level
7.0mmol/L
self-reported
- - -
Liu China enzymatic
method
<200mg/dL
5.18mmol/L
phosphotun
gstic acid
/MgCl2
precipitatio
n
method.
<35mg/dL
0.91mmol/L
FPG.
enzymatic
method
<140mg/dL
7.8mmol/L
- - -
Menotti Italy (mg/dl)
5 classes:
<180
180-219
220-259
260-299
300+
- 0 =absent;
1 =present
- - -
NIPPON
DATA
80
Japan (mg/dl)
sequential
auto
-analyzer.
6categories:
160–179
180–199
200–219
220–239
240–259
260–279
- neocuproine
method §
2 categories:
<200
≥200
(mg/dl)
- - -
Cox UK ratio of TC to HDL
levels
- 1st
CVD
aged
<60
(yes
no)
Height
weght
-
Jee Korea (mg/dL)
<200
200–239
≥240
- FPG
≥6.99mmol/L
≥126mg/dL
- Height
weght
asking
"regular"
(yes/no)
Table 13. Characteristics of the predictors in other countries
HDL = high-density lipoprotein; DM = Diabetes Mellitus; FM = Family history; BMI = body
mass index; FPG = fasting plasma glucose; TC = total cholesterol
* The first author
§ Non-fasting blood samples were drawn and centrifuged within 60 min of collection, and then
stored at -70°C until analyses.
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4.3. Characteristics of the predictors in the validation and calibration
study
The continuous variables used were the age, BP, total cholesterol,
triglycerides, and hs-CRP; and the nominal variables used were the race,
smoking habit, DM history, and statin therapy.
Table 14. D’Agostino et al., Muntner et al., and DeFilippis et al. analyzed
the correlation of the races with the sample scores. The ARIC, PHS, HHP,
PR, SHS, and CHS of the whites, blacks, Native Americans, Japanese
American men, and Hispanic men were compared to those in the
Framingham Study (D’Agostino et al., 2001). The ACC/AHA-pooled cohort
risk and the Framingham Study of the whites and blacks were compared
(Muntner et al., 2014). The MESA and the Framingham Study of the
white, African American, and Hispanic races were validated (DeFilippis et
al., 2015).
Table 15. Aarabi et al. (2005) added score to adjust the total cholesterol
by 0.5-3.2 mmol/L, the TC:HDL ratio by 0.5-2.0 mmol/L, and the
multiplying TC:HDL by 1.1-2.0 mmol/L. Muntner et al. (2014) associated
the self-reported prior diagnosis of diabetes with current use of insulin and
oral hypoglycemic medications.
Table 16. Muntner et al. (2014) reviewed the digoxin and statin therapy
at the baseline. DeFilippis et al. (2015) combined the hs-CRP level (IQR)
in their study.
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Author* AnalysisCohort§ Race Age
BP
(mm Hg) Smoking
SBP DBP
D'Agostino ARIC
PHS
HHP
PR
SHS
CHS
whites,
blacks,
Native
Americans
, Japanese
American
men,
Hispanic
men
30-74 Optimal (SBP<120, DBP<80)
Normal (SBP<130, DBP<85)
High normal
(SBP<140,DBP<90)
Stage I HTN
(SBP<160, DBP<100)
Stage II-IV HTN
(SBP≥160, DBP≥100)
Current
Hense MONICA
Augsburg
PROCAM
- 35-64 measure - self
-report
(1/day)
Marrugat Girona - 34-74 Optimal (SBP<120, DBP<80)
Normal
(SBP120-129, DBP80-84)
Normal high
(SBP130-139, DBP85-89)
Degree I
(SBP140-159, DBP90-99)
Degrees II-III
(SBP≥160, DBP100)
non-
smoking,
smoking
Aarabi HSE - 35-64 add 10-60
to SBP
(Adjustmen)
- -
Jee KHS - 30-74 Optimal+normal
High normal
Stage 1 1
Stage 2–4
(yes/no)
Muntner ACC/AHA
pooled
Cohort
risk
Equations
whites
blacks
45-79 measure status
DeFilippis MESA white,
african
american,
hispanic
Mean
age
measure
Mean SBP
- Never,
Former,
Current
Table 14. Characteristics of the predictors in the validation and
calibration study
BP = blood pressure; SBP = systolic blood pressure; DBP =diastolic blood pressure; HTN =
hypertension; ARIC = the Atherosclerosis Risk in Communities Study(1987-1988); PHS =
Physicians’ Health Study(1982); HHP = Honolulu Heart Program(1980-1982); PR =Puerto Rico
Heart Health Program(1965-1968); SHS = Strong Heart Study(1989-1991); CHS = Cardiovascular
Health Study(1989-1990); MONICA = Monitoring Of Trends and determinants In Cardiovascular
disease surveys; PROCAM = Prospective Cardiovascular Muenster Study from northwestern
Germany; Girona = the Spanish population study; HSE = the Health Survey for England; KHS
= the Korean Heart Study ACC/AHA =American College of Cardiology and the American
Heart Association; REGARDS = the REasons for Geographic And Racial Differences in Stroke
study;; MESA = Multi-Ethnic Study of Atherosclerosis * The first author § compared with the
framingham study
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Author AnalysisCohort§
Cholesterol Glucose /DMTC HDL LDL TG
D'Agostino ARIC
PHS
HHP
PR
SHS
CHS
(mg/dL)
<160
160-199
200-239
240-279
≥280
(mg/dL)
<35
35-44
45-49
50-59
≥60
- - DM
Hense MONICA
Augsburg
PROCAM
MONICA Augsburg:
Augsburg Hospital using
identical methods
ROCAM:
FPG (after a 12-h)
- - MONICA:
Non-fasting blood
samples were
drawn under
standardised
conditions.
PROCAM:
FPG questionnaire
Marrugat Girona (mg/dL)
<160
160-199
200-239
240-279
≥280
(mg/dL)
<35
35-44
45-49
50-59
>59
- - DM
Aarabi HSE add
0.5-3.2
mmol/L
to TC
(adjust)
(adjust)
TC: HDL
ratio; add
0.5–2.0
Multiplying
TC: HDL
ratio add
1.1–2.0
- - -
Jee KHS - (mg/dL)
<35
35–44
45–49
50–59
≥60
(mg/dL)
<130
130-159
≥160
- DM
(yes/no)
Muntner
REGARDS
measured using the Ortho Vitros Clinical Chemistry System
950IRC instrument
Friedewald equation <400
mg/dL
glucose
≥126mg/dL
(fasting)
≥200mg/dL
(nonfasting),
self-report (prior
diagnosis of
diabetes with
current use of
insulin, oral
hypoglycemic
Table 15. Characteristics of the predictors in the validation and
calibration study
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medications)
DeFilippis MESA Mean level
mmol/L,
mg/dL
Mean HDL cholesterol
level mmol/L, mg/dL
- mean HbA1c level
(proportion of total
hemoglobin level)
Author* AnalysisCohort§ History
HTN
-med. BMI
Statin
therapy hs-CRP
D'Agostino ARIC, PHS,
HHP, PR,
SHS, CHS
- - - - -
Hense MONICA
Augsburg ,
PROCAM
- - - - -
Marrugat Ginona - - - - -
Aarabi HSE - - - - -
Jee KHS - - - - -
Muntner ACC/AHA
pooled Cohort
risk
Equations
Atrial
fibrillation,
History of
CHD
review,
Digoxin
use
- review,
statins at
baseline
-
DeFilippis MESA heart attack
(yes,no)
- Mean
kg/m2
- (nmol/L)
Median
hs-CRP
level (IQR)
TC = total cholesterol; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG =
triglyceride; DM = Diabetes Mellitus; HbA1c = hemoglobin A1c; FPG = fasting plasma glucose;
ARIC = the Atherosclerosis Risk in Communities Study(1987-1988); PHS = Physicians’ Health
Study(1982); HHP = Honolulu Heart Program(1980-1982); PR =Puerto Rico Heart Health
Program(1965-1968); SHS = Strong Heart Study(1989-1991); CHS = Cardiovascular Health
Study(1989-1990); MONICA = Monitoring Of Trends and determinants In Cardiovascular disease
surveys; PROCAM = Prospective Cardiovascular Muenster Study from northwestern Germany;
Girona = the Spanish population study; HSE = the Health Survey for England; ACC/AHA
=American College of Cardiology and the American Heart Association; REGARDS = the REasons
for Geographic And Racial Differences in Stroke study; MESA = MESA Multi-Ethnic Study of
Atherosclerosis * The first author § compared with the framingham study
Table 16. Characteristics of the predictors in the validation and
calibration study
HTN-med.= hypertension medication status; BMI = body mass index; hs-CRP = high-sensitivity
C-reactive protein; ARIC = the Atherosclerosis Risk in Communities Study(1987-1988); PHS =
Physicians’ Health Study(1982); HHP = Honolulu Heart Program(1980-1982); PR =Puerto Rico Heart
Health Program(1965-1968); SHS = Strong Heart Study(1989-1991); CHS = Cardiovascular Health
Study(1989-1990); MONICA = Monitoring Of Trends and determinants In Cardiovascular disease
surveys; PROCAM = Prospective Cardiovascular Muenster Study from northwestern Germany;
Girona = the Spanish population study; HSE = the Health Survey for England; ACC/AHA
=American College of Cardiology and the American Heart Association; REGARDS = the REasons
for Geographic And Racial Differences in Stroke study; MESA = MESA Multi-Ethnic Study of
Atherosclerosis; CHD= coronary heart disease * The first author
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Ⅳ. DISCUSSION
This study is a historical review of the prediction model for ASCVD.
Many researchers have used, developed, and provided to many people the
Framingham Study in the USA. Framingham functions have overestimated
the CHD risk in some populations, which has raised the concern that it
may be inappropriate for other populations (Hense et al., 2003). The
10-year CHD event rates were 1.5% for men and 0.6% for women in the
CMCS, without adjusting for the age. The corresponding crude incidence
rates in Framingham men and women were 8.0% and 2.8%, respectively
(Liu et al., 2004). The proportion of cells in which the 10-year probability
of developing a CHD event was > 9% was 2.3 times higher, and that of
cells with a probability >19% was 13 times lower, in the chart calibrated
for Spain than in the original Framingham charts (Marrugat et al., 2003).
The 10-year ASCVD risk for men in the KHS cohort was overestimated
by 56.5% (White model) and 74.1% (AA model), whereas the risk for
women was underestimated by 27.9% (White model) and overestimated by
29.1% (AA model) (Jung et al., 2015). Each country added was set up to
reflect the characteristics of the prediction model. Further research is
needed to enhance the prediction capability of individual models from the
Framingham scores though the validation and calibration.
In the statistical analysis model, the logistic regression model of the
characteristics of the statistical analysis assumed the specified time period
given a set of variables. The Cox proportional hazards regression assumed
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that for each individual, values of one or more explanatory variables were
available. Therefore, the statistical analysis showed a trend from logistic
regression to the Cox proportional hazards model in the USA, other
countries, and the validation and calibration study.
The definition of the outcomes was expanded from CHD and not CHD to
hard CHD or CVD in the USA. In the study in other countries, the
outcomes were defined as ICD codes, and the incidence of CVD or death
probabilities, hard CHD or CVD. In the validation and calibration study, the
definition of the outcomes was expanded to ASCVD.
The general risk factors of the prediction model combined the narrowing
factor, cholesterol, to expanding variables such as the DM, smoking habit,
family history, HTN medication, statin therapy, and exercise.
The ages were stratified into young age, middle age, and old age.
However, the study was conducted among the young people, because the
incidence of CVD is increasing among them. The races differed among the
multiple ethnic groups, so a genetic risk score had to be included. In the
BP, glucose, and cholesterol level, the same baseline method had to be set.
The family history was a strong factor of the atrial fibrillation, history of
CHD (Muntner et al., 2014), and heart attack (DeFilippis et al., 2015). The
HTN medication was a good type of digoxin (Muntner et al., 2014) and
antihypertensives, thiazide, β blocker, CCB, and ACE inhibitor (Cox et al.,
2007). DM had to have a common baseline score in the continuous
variables, and the last diagnosis of diabetes was correlated with the
current use of insulin and oral hypoglycemic medications among the
nominal variables, as surfaced by the questionnaire. In the statin therapy,
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an absolute baseline had to be set up worldwide. Exercise should be
included in the regimen for the prevention of ASCVD.
Estimation of the absolute cerebrovascular disease risk, which is required
for its common treatment and prevention, relies on prediction models
developed from the experience of prospective cohort studies (D’Agostino et
al., 2001).
To prevent ASCVD, efforts should be made to develop an accurate
prediction model.
Those with a healthy lifestyle had an 80% lower risk of a first stroke
than those who did not (Chiuve et al., 2008). Therefore, we should consider
our lifestyle, such as how much time we go for a walk, how much junk
food we eat, and by how much we relieve our stress or stress level.
This literature review had some limitations, as follows.
First, we focused on the general characteristics of the model, the
outcome, and the risk factors without the results of the literature review.
Second, in the assessment of the model performance, we were introduced
to the characteristics by evaluating the model using the same data as
those in the validation and calibration study. Third, we did not consider
up-to-date risk factors such as novel biomarkers, the genetic risk score,
and single-nucleotide polymorphisms (SNPs).
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V. CONCLUSION
In this report, we reviewed literature on the history of ASCVD prediction
models.
In summary, the Framingham Study was applied to the risk functions
obtained through the literature review. The Framingham algorithm
over-predicted the risk of ASCVD through validation and calibration in a
modern multi-ethnic cohort. A shift in risk estimation provided more
contemporary approaches to estimating the risk of ASCVD and to
discriminating better those at high risk such as based on their age, race,
sex, antihypertensive treatment, statin use, exercise, and family history of
social deprivation. This study may support the need for baseline
information in ASCVD prediction models.
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ABSTRACT(IN KOREAN)
심뇌혈관 질환 예측모형 발전사의 문헌적 고찰
<지도 교수 지선하>
연세대학교 보건대학원 역학건강증진
박현희
배경: 심뇌혈관 질환은 세계적으로 주요 사망원인이다. 프레밍험 연구는 지역
과 인종간의 차이로 과다 측정되어 세계 모든 인구에 적용하는 것은 주의가
요구된다. 그리하여 각 나라에서는 심뇌혈관 질환을 예방하고자 정교한 모형
을 개발하기 위해 노력하고 있다.
목적: 예측모형의 역사를 체계적인 문헌고찰을 통해 일반적 특성, 일반적인
특성의 모형과 결과, 고 위험 요인, 예측 요인들로 분석하였다.
방법: 펌메드 PubMed와 구글 스콜라 Google Scholar에서 문헌 고찰하였다.
결과: 통계 분석은 미국, 나라별, 비교 및 측정 논문 모두 로지스틱 모형에서
콕스 모형으로 변화하였다. 결과 정의에서 미국 모형은 심장질환과 비심장질
환에서 강력한 심장질환 또는 뇌혈관질환으로 확장되었다. 나라별 모형에서는
국제 질환 분류 코드, 뇌혈관 질환 발생률, 사망률, 강력한 심혈관 질환 또는
뇌혈관질환으로 정의하였다. 비교 및 측정 논문에서는 죽상경화성 심장질환으
로 확대 되었다.
예측모형의 일반적 고위험 요인은 콜레스테롤의 좁은 의미에서 당뇨병, 흡연,
가족력, 고혈압약 복용, 고지혈증치료제, 운동의 다양한 요인으로 확장되었다.
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핵심되는 말: 심뇌혈관 질환, 연구, 일반적 특성, 위험 요인, 예측요인
결론: 본 연구는 심뇌혈관 질환의 예측 모형의 기준을 위해 중요한 정보를 제
공하기 위함이다.
